Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026

Champions Oncology (NASDAQ:CSBR) will report its financial and operational results for the fourth quarter and year ended April 30, 2026 on Monday, July 27, 2026, after market close.

Rhea-AI Summary

Champions Oncology (NASDAQ:CSBR) will report its financial and operational results for the fourth quarter and year ended April 30, 2026 on Monday, July 27, 2026, after market close. Management will discuss the results on a conference call that day at 4:30 P.M. ET (1:30 P.M. PT).

Investors can join the call by dialing 888-506-0062 (Domestic) or 973-528-0011 (International) with access code 347142. A replay will be available at 877-481-4010 (Domestic) or 919-882-2331 (International), passcode 54320, and in the investors section of the company’s website within 72 hours. According to Champions Oncology, the company provides global preclinical and clinical oncology research services and data platforms to biopharma organizations.

Market Context

The two prior earnings-date announcements were followed by 2.44% and 0.16% 24-hour reactions, while ...

Analysis

The two prior earnings-date announcements were followed by 2.44% and 0.16% 24-hour reactions, while current short positioning was low. That record frames the notice as a scheduling event; the July 27 results remain the substantive checkpoint.

Key Figures

Reporting date: July 27, 2026 Fiscal period end: April 30, 2026 Conference call time: 4:30 P.M. ET +1 more

Reporting date

July 27, 2026

Fourth-quarter and year-end results announcement

Fiscal period end

April 30, 2026

Quarter and year ended

Conference call time

4:30 P.M. ET

July 27, 2026

Replay availability

72 hours

Company website replay availability

Previous Earnings date Reports

2 past events · Latest: Mar 05

Same Type 2 events

1. Mar 05

   Earnings date

   24h Move

   +2.4%

   Third-quarter results announcement scheduled after market close with a conference call

2. Dec 08

   Earnings date

   24h Move

   +0.2%

   Second-quarter results announcement scheduled after market close with conference-call details

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

patient-derived xenograft, in vivo, ex vivo

3 terms

patient-derived xenograft medical

"patient-derived xenograft (PDX) and primary hematological malignancy models"

A patient-derived xenograft (PDX) is a laboratory model created by implanting a tumor or diseased tissue taken directly from a human patient into an animal host that can support its growth. Because PDX models tend to mirror how a human tumor behaves and responds to treatments better than simple cell cultures, investors view their use as a stronger signal that preclinical drug results may translate to patients, lowering development risk much like a full-scale dress rehearsal raises confidence before opening night.

in vivo medical

"proprietary in vivo and ex vivo platforms"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

ex vivo medical

"proprietary in vivo and ex vivo platforms"

Ex vivo describes tests or treatments performed on living cells, tissues, or organs that have been removed from the body and studied in an external environment. For investors, ex vivo work sits between basic lab dish tests and whole‑animal or human studies, offering a more realistic preview of how a therapy or diagnostic might behave in real tissue — like running an engine on a test stand before putting it back into a car — which can reduce scientific risk and inform development milestones.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HACKENSACK, NJ / ACCESS Newswire / July 20, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter and year ended April 30, 2026, on Monday, July 27, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. ET (1:30 P.M. PT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 347142. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 54320, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions and innovative data platforms to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

Media Inquiries:

Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com

Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/

SOURCE: Champions Oncology, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Champions Oncology (NASDAQ: CSBR) report its Q4 and year-end 2026 financial results?

Champions Oncology will report its fourth quarter and year-end 2026 financial and operational results on Monday, July 27, 2026, after market close. According to Champions Oncology, these results cover the period ended April 30, 2026.

What time is the Champions Oncology (CSBR) earnings conference call on July 27, 2026?

The Champions Oncology earnings conference call is scheduled for 4:30 P.M. ET (1:30 P.M. PT) on July 27, 2026. According to Champions Oncology, the call will follow the release of fourth quarter and year-end 2026 results after market close.

How can investors join the Champions Oncology (CSBR) Q4 2026 earnings call by phone?

Investors can join the Champions Oncology earnings call by dialing 888-506-0062 (Domestic) or 973-528-0011 (International) and entering access code 347142. According to Champions Oncology, the call is on July 27, 2026, at 4:30 P.M. ET.

Is there a replay available for the Champions Oncology (CSBR) July 27, 2026 earnings call?

Yes. A replay will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode 54320. According to Champions Oncology, the replay will also be accessible in the investors section of its website within 72 hours.

What period do the Champions Oncology (CSBR) year-end 2026 results cover?

The year-end 2026 results cover the fiscal year ended April 30, 2026. According to Champions Oncology, both the fourth quarter and full-year financial and operational results for this period will be reported on July 27, 2026.

What type of business does Champions Oncology (NASDAQ: CSBR) operate?

Champions Oncology operates as a global preclinical and clinical research services provider focused on oncology. According to Champions Oncology, it offers end-to-end oncology R&D solutions, patient-derived xenograft models, bioanalytical platforms, and data analytics to biopharma organizations worldwide.